thiazolidines has been researched along with Diabetes Mellitus, Adult-Onset in 113 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (8.85) | 18.2507 |
| 2000's | 18 (15.93) | 29.6817 |
| 2010's | 59 (52.21) | 24.3611 |
| 2020's | 26 (23.01) | 2.80 |
| Authors | Studies |
|---|---|
| Hosoda, K; Kasahara, M; Kasama, S; Makino, H; Miyamoto, Y; Nishimura, K; Nishimura, T; Ogawa, Y; Son, C; Tanaka, T; Taneda, S | 1 |
| Erande, S; Saboo, B; Unnikrishnan, AG | 1 |
| Inagaki, N; Iwasaki, T; Kadowaki, T; Mori-Anai, K; Sasaki, K; Teranishi, T; Watada, H | 1 |
| Kim, JH; Lee, BW; Lee, M; Lee, WJ | 1 |
| Alimuddin, S; Bhosle, D; Chandekar, B | 1 |
| Bhondve, A; Joshi, S; Kulkarni, P; Mansoori, S; Medidar, R; Modh, K; Nasikkar, N; Panikar, K; Panikar, V; Sachdev, I; Tiwaskar, M; Tuteja, H; Walawalkar, S | 1 |
| Bayannavar, PK; Bheemayya, L; Hoolageri, SR; Joshi, SD; Kamble, RR; Kodasi, B; Kumbar, VM; Metre, TV; Nadoni, VB; Shettar, AK | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kawata, S; Kurihara, Y; Manda, N; Miyoshi, H; Nagai, S; Nakamura, A; Nomoto, H; Omori, K; Sugawara, H; Takeuchi, J; Tsuchida, K; Yokoyama, H | 1 |
| Kasthuri, S; Mohan, V; Poongothai, S; Ramu, M | 1 |
| Haneda, M; Ito, H; Kadowaki, T; Matsukawa, M; Sasaki, K; Yamada, Y | 1 |
| Kashiv, P; Kumar, J | 1 |
| Hatware, K; Patil, K; Sharma, R; Sharma, S | 1 |
| Guo, D; Kudo, K; Mizukami, H; Ogasawara, S; Osonoi, S; Sasaki, T; Takahashi, K; Yagihashi, S | 1 |
| Akimoto, H; Asai, S; Nakayama, T; Nishida, Y; Takahashi, Y; Tezuka, K | 1 |
| Haneda, M; Ito, H; Kadowaki, T; Sasaki, K; Yamada, Y | 1 |
| Fushimi, Y; Hirukawa, H; Horiya, M; Iwamoto, Y; Kaku, K; Kan, Y; Kaneto, H; Kinoshita, T; Kohara, K; Mashiko, A; Mizoguchi-Tomita, A; Mune, T; Nakanishi, S; Nishioka, M; Obata, A; Okauchi, S; Sanada, J; Shimoda, M; Tatsumi, F | 1 |
| Aso, Y; Iijima, T; Jojima, T; Kase, M; Sagara, M; Sakurai, S; Tomaru, T; Usui, I | 1 |
| Elumalai, S; Karunakaran, U; Moon, JS; Won, KC | 1 |
| Chahal, S; Syngle, A; Vohra, K | 1 |
| Ji, L; Li, W; Liu, J; Lu, W; Ma, J; Takayanagi, G; Wang, Y; Xiao, X; Yang, J; Zeng, J; Zhang, X | 1 |
| Mori-Anai, K; Nakada, T; Nakamaru, Y; Saito, R; Takahata, T; Tashima, Y | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kawata, S; Kurihara, Y; Miya, A; Miyoshi, H; Nagai, S; Nakamura, A; Nomoto, H; Omori, K; Sugawara, H; Takeuchi, J; Taneda, S; Tsuchida, K; Yokoyama, H | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kawata, S; Kurihara, Y; Miya, A; Miyoshi, H; Nagai, S; Nakamura, A; Nishimoto, N; Nomoto, H; Omori, K; Shigesawa, I; Sugawara, H; Takeuchi, J; Taneda, S; Tsuchida, K; Yanagiya, S; Yokoyama, H | 1 |
| Ha, KH; Kim, DJ; Kim, SH; Seo, DH | 1 |
| Bougrin, K; Cherrah, Y; El Achouri, M; Faouzi, MEA; Fettach, S; Hafidi, Z; Karrouchi, K; Sefrioui, H; Tachallait, H; Thari, FZ | 1 |
| Bae, JC; Cha, JE; Hwang, YC; Hyun, BJ; Kim, HJ; Kim, JH; Kim, SY; Kwak, SH; Suh, S; Won, JC | 1 |
| Baidya, A; Bhattacharjee, R; Chadha, M; Chowdhury, S; Das, S; Ghosh, S; Giri, D; Goswami, S; Maiti, A; Majumder, A; Roy, A; Sahana, PK; Sanyal, D; Sinha, A | 1 |
| Gouda, M; Iijima, H; Inagaki, N; Kadowaki, T; Kaneko, G; Kondo, K; Maruyama, N; Nakanishi, N; Nishimura, K; Watanabe, Y | 3 |
| Gouda, M; Kadowaki, T; Kondo, K; Miyayama, K; Sasaki, N; Terata, R; Yokota, S | 1 |
| Chen, Y; Cheng, J; Deng, X; He, H; Huang, W; Jiang, H; Jiang, W; Jin, T; Liu, Q; Tao, J; Wang, A; Wang, C; Ye, J; Zhou, R | 1 |
| Haneda, M; Iijima, H; Ito, H; Kadowaki, T; Kimura, M; Matsukawa, M; Sasaki, K; Ueno, M; Yamakura, T | 1 |
| Aihara, M; Hashimoto, T; Ishii, N; Izumi, K; Kage, Y; Nishie, W; Shimizu, H; Uchida, T; Yamaguchi, Y | 1 |
| Fujita, Y; Iwata, H; Izumi, K; Mai, Y; Morita, Y; Nishie, W; Nomura, T; Sato-Matsumura, KC; Shimizu, H; Shimizu, S; Toyonaga, E; Ujiie, H; Watanabe, M; Yoshimoto, N | 1 |
| Haneda, M; Hiraide, S; Ito, H; Kadowaki, T; Matsukawa, M; Sasaki, K; Ueno, M | 1 |
| Takahashi, H; Yajima, K; Yajima, T; Yasuda, K | 1 |
| Fujii, M; Iida, Y; Kanasaki, K; Kitada, M; Konishi, K; Koya, D; Nakagawa, A; Nitta, K; Ogura, Y | 1 |
| Kondo, Y; Mitsumatsu, T; Okahata, S; Sakamoto, K; Shiba, T; Tanaka, S | 1 |
| Aggarwal, D; Bishnoi, A; Guliani, A; Parsad, D | 1 |
| Adornato, I; Balestri, F; Cappiello, M; Del Corso, A; Lori, G; Maccari, R; Naß, A; Ottanà, R; Paoli, P; Wolber, G | 1 |
| Choi, KM; Jang, HC; Kang, ES; Kim, DJ; Kim, ES; Kim, NH; Kim, SJ; Kim, SR; Kim, Y; Lee, MK; Oh, T; You, J | 1 |
| Hamasaki, T; Imazu, M; Ito, S; Kitakaze, M; Nakano, A | 1 |
| Ceriello, A; De Nigris, V; Gouda, M; Iijima, H; Matsui, T | 1 |
| Agrawal, P; Gautam, A; Maheshwari, PK; Pursnani, N | 1 |
| Chandra, R; Dubey, M; Kumari, K; Pandey, ND; Singh, P; Vishvakarma, VK | 1 |
| Kadowaki, T; Kondo, K | 2 |
| Haq, W; Katti, SB; Raza, S; Srivastava, AK; Srivastava, DS; Srivastava, SP | 1 |
| Kosaka, T; Kuwahara, Y; Nakamura, K; Otsuki, H; Shimomura, F; Tsukamoto, T | 1 |
| Akahoshi, F; Goda, M; Hayashi, Y; Ishii, S; Terata, R | 1 |
| Goda, M; Kadowaki, T | 1 |
| Ichikawa, T; Kohno, S; Nakao, K; Onitsuka, Y; Takeshima, F | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Aoki, C; Aso, Y; Kato, K; Niitani, M; Suzuki, K; Tanaka, S; Tomotsune, T | 1 |
| Aoki, K; Ashiya, Y; Kamiko, K; Kamiyama, H; Minagawa, F; Nakajima, S; Shibata, E; Shinoda, K; Taguri, M; Terauchi, Y | 1 |
| Nakamura, S; Nakazato, M; Sakoda, H; Tsubouchi, C; Tsuchimochi, W; Ueno, H; Yamashita, E | 1 |
| Kusunoki, M; Miyata, T; Nakamura, T; Natsume, Y; Oshida, Y; Sato, D; Tsutsui, H; Tsutsumi, K | 1 |
| Abiru, N; Ando, T; Fujishima, K; Haraguchi, A; Imaizumi, M; Kawakami, A; Matsumoto, K; Mori, F; Takamura, N; Yamasaki, H | 1 |
| Cha, BY; Chul Jang, HC; Chung, CH; Han, KA; Jang, WI; Kim, KA; Kim, MK; Ku, BJ; Lee, HW; Lee, MK; Park, IB; Park, JY; Park, KS; Rhee, EJ; Woo, AC | 1 |
| Morishita, R; Nakagami, H | 1 |
| Kobayashi, M; Ueki, K | 1 |
| Iijima, H; Kadowaki, T; Katoh, M; Marubayashi, F; Yokota, S | 1 |
| Arakawa, K; Hikida, K; Ikenaga, Y; Kiuchi, S; Kuriyama, C; Matsushita, Y; Nakamaru, Y; Nakayama, K; Oguma, T; Oka, K; Saito, A; Shiotani, M; Ueta, K; Yoshida, K | 1 |
| Fujiwara, S; Nagai, H; Nishigori, C; Takahashi, Y | 1 |
| Fukui, T; Hara, N; Hayashi, T; Higuchi, A; Hirano, T; Ito, R; Ohara, M; Osamura, A; Yamamoto, T | 1 |
| Ishii, Y; Ito, T; Kashimura, A; Saito, S; Sameshima, A; Sasahara, M; Sasaoka, T; Sawakawa, K; Tsuneki, H; Wada, T; Yonezawa, R | 1 |
| Ako, J; Fujiyoshi, K; Hashikata, T; Hashimoto, T; Kakizaki, R; Kameda, R; Kitasato, L; Maekawa, E; Namba, S; Nemoto, T; Shimohama, T; Tojo, T; Yamaoka-Tojo, M | 1 |
| Gu, W; Guo, X; Ji, L; Lu, J | 1 |
| Scott, LJ | 1 |
| Ahn, CW; Cho, YW; Chung, CH; Han, KA; Hong, S; Jang, HC; Ku, BJ; Lee, CB; Lee, MK; Moon, MK; Park, CY; Park, SW; Son, HS | 1 |
| Bryson, A; Deak, L; Jennings, PE; Lawson, M; Paveliu, FS | 1 |
| Aoki, C; Aso, Y; Inoue, T; Sagara, M; Suzuki, K; Taguchi, I; Tanaka, S | 1 |
| Kutoh, E; Terayama, S; Wada, A | 1 |
| Emoto, N; Hattori, N; Nagamine, T; Nakamura, Y; Okajima, F; Sugihara, H | 1 |
| Hayashi, M; Takahashi, H; Yajima, K; Yajima, T; Yasuda, K | 1 |
| Atsumi, Y; Baba, M; Hotta, N; Kawamori, R; Kishikawa, H; Nakamura, J; Oikawa, S; Shigeta, Y; Yamada, N; Yasuda, H | 1 |
| Azuma, K; Fujitani, Y; Hirose, T; Ikeda, F; Kanazawa, A; Kawamori, R; Ohmura, C; Shimizu, T; Tanaka, Y; Watada, H; Yoshihara, T | 1 |
| Woo, V | 1 |
| Bassett, K; Carleton, B; Carney, G; Dormuth, CR; Wright, JM | 1 |
| Beck-Nielsen, H; Home, PD; Jones, NP; Kahn, SE; Noronha, D; Viberti, G | 1 |
| Chai, Q; Li, J; Li, JY; Li, YY; Liu, Z; Ma, LP; Shen, JK; Shen, Q; Sheng, L; Wang, X; Zhang, LN | 1 |
| Choe, SS; Choi, EB; Chung, H; Jeong, HW; Kim, HS; Kim, JB; Kim, KH; Kim, WS; Lee, GY; Lee, H; Lee, HK; Lee, JH; Lee, JW; Park, HS; Park, KS; Park, SB; Ro, S; Shin, D; Shin, HJ | 1 |
| Schwanstecher, C; Schwanstecher, M | 1 |
| Hosoda, K | 1 |
| Hirose, T | 1 |
| Eto, T; Inoue, S; Kadowaki, T | 1 |
| Abe, Y; Akahoshi, F; Anabuki, J; Fukuda, S; Hayashi, Y; Ishige, T; Ishii, S; Kishida, H; Kitajima, H; Kiuchi, S; Kosaka, K; Masutomi, N; Miyaguchi, I; Murozono, T; Nabeno, M; Nakamaru, Y; Nakamura, M; Sakashita, H; Sekiguchi, S; Shima, K; Soejima, A; Sonda, S; Takashina, Y; Takeuchi, M; Tanaka, Y; Tsutsumiuchi, R; Ueda, N; Utsumi, H; Yoshida, K; Yoshida, T | 1 |
| Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K | 1 |
| Aoyama, I; Enomoto, A; Nakamura, S; Niwa, T; Tachikawa, T; Takayama, F; Tobita, K | 1 |
| Calkin, AC; Cooper, ME; Thomas, MC | 1 |
| Narce, M; Poisson, JP | 1 |
| Arch, JR; Augstein, P; Cawthorne, MA; Demuth, HU; Heinke, P; Hoffmann, T; Meyer, A; Sennitt, MV; Stocker, C; Subramanian, A; Wargent, E | 1 |
| Hattori, T; Kanai, K; Kuwabara, S; Misawa, S; Nakata, M; Sawai, S; Tamura, N; Yagui, K | 1 |
| Akahoshi, F; Hayashi, Y; Sakashita, H; Yoshida, T | 1 |
| Akanuma, Y; Hotta, N; Kawamori, R; Matsuoka, K; Oka, Y; Sakamoto, N; Shichiri, M; Shigeta, Y; Toyota, T | 1 |
| Eto, M; Katsuyama, S; Miura, M; Mohri, K; Mouri, K; Mukai, J; Shoji, T; Suzuki, T; Tada, H; Watanabe, Y | 1 |
| Gross, B; Staels, B | 1 |
| Dorais, M; LeLorier, J | 1 |
| Gleissner, CA; Ley, K; Nadler, J; Sanders, JM | 1 |
| Hamada, Y; Hotta, N; Koh, N; Naruse, K; Odagaki, Y; Sakakibara, F | 1 |
| Araki, N; Hamada, Y; Horiuchi, S; Hotta, N | 1 |
| Fujii, W; Ishikawa, S; Kawata, T; Koike, T; Makita, Z; Nakamura, S; Yanagisawa, K; Yasumura, K | 1 |
| Kashima, K; Mori, M; Ohtani, K; Sato, N; Shimizu, H; Uehara, Y | 1 |
| Nakamura, T; Okano, R; Okuda, S; Seo, Y; Uchiyama, H | 1 |
| Aono, T; Fujita, T; Hamada, M; Hayakawa, N; Hayashi, R; Itoh, M; Kakizawa, H; Makino, M; Nagasaka, A; Nagata, M; Shinohara, R; Uchimura, K | 1 |
| Inaba, M; Kawagishi, T; Kyogoku, I; Miki, T; Morii, H; Nishizawa, Y; Okuno, Y; Shimada, H | 1 |
| Kariyone, S; Nakatani, Y; Narabayashi, I; Onishi, S; Saika, Y; Tamura, K; Utsunomiya, K | 1 |
| Atsumi, T; Ishida, M; Ishikawa, S; Koike, T; Makita, Z; Miyoshi, H; Obara, S; Tsuchida, K; Yamagishi, S; Yasumura, K | 1 |
| Ikeda, T; Iwata, K; Tanaka, Y | 1 |
| Haneda, M; Hirai, A; Joko, M; Kashiwagi, A; Kawabata, T; Kikkawa, R; Maeda, K; Maeda, T; Terada, M; Yasuda, H | 1 |
| Hamada, Y; Horiuchi, S; Hotta, N; Kasuya, Y; Kato, K; Komori, T; Nagai, R; Nakamura, J; Naruse, K | 1 |
| Chaya, S; Hamada, Y; Hotta, N; Kamiya, H; Koh, N; Mizubayashi, R; Nakamura, J; Nakayama, M; Yasuda, Y | 1 |
13 review(s) available for thiazolidines and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon-Like Peptide 1; Half-Life; Humans; Pyrazoles; Thiazolidines | 2020 |
The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Child; Child, Preschool; Cytochrome P-450 CYP3A; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Infant; Infant, Newborn; Japan; Male; Middle Aged; Oxygenases; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2019 |
[Pharmacological and clinical profile of a novel DPP-4 inhibitor teneligliptin hydrobromide hydrate (TENELIA(®)].
Topics: Adult; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazoles; Rats; Rats, Zucker; Thiazolidines | 2013 |
Teneligliptin for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pyrazoles; Thiazolidines | 2013 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Teneligliptin : expectations for its pleiotropic action.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Pyrazoles; Thiazolidines | 2015 |
Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.
Topics: Asian People; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazoles; Thiazolidines | 2015 |
Teneligliptin: a review in type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Pyrazoles; Thiazolidines | 2015 |
Targeting type 2 diabetes.
Topics: Adipose Tissue; Caloric Restriction; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Metformin; Signal Transduction; Thiazolidines | 2011 |
[Thiazolidine derivatives].
Topics: Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Thiazolidines | 2011 |
MK-767. Kyorin/Banyu/Merck.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidines | 2003 |
Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review.
Topics: Administration, Oral; Biguanides; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycated Hemoglobin; Glycoside Hydrolases; Humans; Hypoglycemic Agents; Lipids; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidines | 2007 |
PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Homeostasis; Humans; Insulin; Insulin Resistance; Lipid Metabolism; Lipoproteins; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidines | 2007 |
37 trial(s) available for thiazolidines and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucose; Humans; Hypoglycemic Agents; Japan; Prospective Studies; Risk Factors; Sodium; Thiazolidines | 2021 |
Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Prospective Studies; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Treatment Outcome | 2022 |
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Prospective Studies; Pyrazoles; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Thiazolidines | 2020 |
A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; India; Prospective Studies; Pyrazoles; Sitagliptin Phosphate; Thiazolidines | 2019 |
Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study.
Topics: Autonomic Nervous System Diseases; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Hand Strength; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrazoles; Quality of Life; Thiazolidines | 2021 |
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyrazoles; Thiazolidines | 2021 |
Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Intestinal Absorption; Kidney; Male; Middle Aged; Models, Biological; Postprandial Period; Pyrazoles; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Young Adult | 2020 |
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Secretion; Japan; Male; Middle Aged; Prospective Studies; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Young Adult | 2021 |
Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
Topics: Adult; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Prospective Studies; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2021 |
Effects of Teneligliptin on HbA1c levels, Continuous Glucose Monitoring-Derived Time in Range and Glycemic Variability in Elderly Patients with T2DM (TEDDY Study).
Topics: Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Pyrazoles; Thiazolidines | 2022 |
Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
Topics: Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet Therapy; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Pyrazoles; Thiazolidines | 2017 |
Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
Topics: Aged; Canagliflozin; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Exercise; Female; Humans; Hyperglycemia; Hypoglycemia; Japan; Male; Membrane Transport Modulators; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2; Thiazolidines | 2018 |
Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
Topics: Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazoles; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2019 |
Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazoles; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidines; Treatment Failure | 2019 |
Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Female; Heart Failure; Humans; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Thiazolidines; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult | 2019 |
Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Pyrazoles; Thiazolidines; Time Factors; Treatment Outcome | 2013 |
Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Inositol; Kidney Failure, Chronic; Male; Middle Aged; Nitriles; Prospective Studies; Pyrazoles; Pyrrolidines; Renal Dialysis; Serum Albumin; Thiazolidines; Vildagliptin | 2014 |
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Postprandial Period; Pyrazoles; Sulfonylurea Compounds; Thiazolidines; Treatment Outcome | 2014 |
Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
Topics: Aged; Albuminuria; Asian People; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Pyrazoles; Thiazolidines; Treatment Outcome | 2015 |
DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Prospective Studies; Pyrazoles; Thiazolidines; Treatment Outcome | 2015 |
Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazoles; Republic of Korea; Thiazolidines | 2015 |
Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Pyrazoles; Thiazolidines; Young Adult | 2015 |
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Topics: Administration, Oral; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Exercise; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Incidence; Insulin Resistance; Patient Compliance; Pyrazoles; Republic of Korea; Thiazolidines; Time Factors | 2016 |
The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pyrazoles; Thiazolidines; Treatment Outcome | 2016 |
Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.
Topics: Aged; Aged, 80 and over; Albuminuria; Case-Control Studies; Diabetes Mellitus, Type 2; Endothelium; Female; Humans; Male; Middle Aged; Oxidative Stress; Pyrazoles; Renal Insufficiency, Chronic; Thiazolidines; Treatment Outcome | 2016 |
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Blood Glucose; Body Weight; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Pyrazoles; Thiazolidines; Treatment Outcome | 2017 |
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Long-Term Care; Male; Middle Aged; Patient Selection; Proteinuria; Rhodanine; Thiazolidines; Treatment Outcome | 2008 |
Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Topics: Adult; Aged; Aldehyde Reductase; beta Carotene; Diabetes Mellitus, Type 2; Down-Regulation; Enzyme Inhibitors; Erythrocytes; Female; Humans; Lipid Peroxidation; Lipid Peroxides; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Rhodanine; Thiazolidines; Thiobarbituric Acid Reactive Substances; Vitamin E | 2009 |
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Thiazolidines; Treatment Outcome | 2010 |
Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Pyrazoles; Thiazolidines; Time Factors; Treatment Outcome | 2012 |
Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
Topics: Adult; Aged; Aged, 80 and over; Aldehyde Reductase; Carpal Tunnel Syndrome; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ion Transport; Male; Median Nerve; Middle Aged; Neural Conduction; Reaction Time; Rhodanine; Sodium; Sodium Channels; Thiazolidines | 2006 |
A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT).
Topics: Age of Onset; Aged; Aldehyde Reductase; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Motor Neurons; Neural Conduction; Prospective Studies; Rhodanine; Thiazolidines | 2007 |
Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients.
Topics: Adult; Aldehyde Reductase; Blood Glucose; Diabetes Mellitus, Type 2; Erythrocytes; Fasting; Female; Fructosephosphates; Hexosephosphates; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Phosphorus Isotopes; Reference Values; Rhodanine; Thiazolidines | 1995 |
Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients.
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; In Vitro Techniques; Luminescent Measurements; Luminol; Male; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Phagocytosis; Reference Values; Rhodanine; Superoxides; Thiazolidines; Time Factors | 1997 |
Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
Topics: Aged; Aged, 80 and over; Aldehyde Reductase; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Electrocardiography; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Rhodanine; Statistics, Nonparametric; Thiazolidines | 1999 |
Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diet, Diabetic; Electrocardiography; Enzyme Inhibitors; Female; Heart Rate; Humans; Hypoglycemic Agents; Insulin; Light; Male; Median Nerve; Middle Aged; Neural Conduction; Reaction Time; Reflex, Pupillary; Respiratory Mechanics; Rhodanine; Thiazolidines; Tibial Nerve | 2001 |
63 other study(ies) available for thiazolidines and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
A prospective multicentre open label study to assess effect of Teneligliptin on glycemic control through parameters of time in range (TIR) Metric using continuous glucose monitoring (TOP-TIR study).
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Glycemic Control; Humans; Prospective Studies; Pyrazoles; Thiazolidines | 2022 |
Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Product Surveillance, Postmarketing; Pyrazoles; Thiazolidines | 2022 |
Evaluation of Teneligliptin a DPP4 Inhibitor in Terms of Efficacy and Safety with Respect to QT/QTc Prolongation in Patients with Type II Diabetes Mellitus (T2DM).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Long QT Syndrome; Pyrazoles; Thiazolidines | 2022 |
Study of the Efficacy of Uptitrating Teneligliptin Dose from Standard Dose (20 mg) to High Dose (40 mg) in Patients with Type II Diabetes Mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Pyrazoles; Retrospective Studies; Thiazolidines | 2022 |
Coumarin-4-yl-1,2,3-triazol-4-yl-methyl-thiazolidine-2,4-diones: Synthesis, glucose uptake activity and cytotoxic evaluation.
Topics: Coumarins; Diabetes Mellitus, Type 2; Glucose; HEK293 Cells; Humans; Molecular Docking Simulation; Thiazolidines; Triazoles | 2023 |
Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrazoles; Socioeconomic Factors; Thiazolidines | 2020 |
Eff ectiveness of Teneligliptin as an Add-on in T2DM Patients not Controlled on Metformin and Glimepiride.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazoles; Sulfonylurea Compounds; Thiazolidines | 2020 |
Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and β-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Canagliflozin; Cell Count; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Hypoglycemic Agents; Insulin-Secreting Cells; Islets of Langerhans; Male; Pancreas; Parasympathetic Nervous System; Pyrazoles; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2020 |
Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Linagliptin; Lipid Metabolism; Lipoproteins, HDL; Male; Middle Aged; Piperidines; Pyrazoles; Sitagliptin Phosphate; Thiazolidines; Triglycerides; Uracil; Vildagliptin | 2020 |
Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrazoles; Thiazolidines | 2020 |
Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Pyrazoles; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Treatment Outcome | 2020 |
Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
Topics: Aged; Chemokine CCL11; Chemokine CCL22; Chemokine CXCL10; Chemokines; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Meals; Middle Aged; Pyrazoles; Thiazolidines | 2020 |
High glucose-induced PRDX3 acetylation contributes to glucotoxicity in pancreatic β-cells: Prevention by Teneligliptin.
Topics: Acetylation; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin-Secreting Cells; Oxidative Stress; Pancreatic Neoplasms; Peroxiredoxin III; Pyrazoles; Src Homology 2 Domain-Containing, Transforming Protein 1; Thiazolidines; Ubiquitin Thiolesterase | 2020 |
Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea.
Topics: Diabetes Mellitus, Type 2; Humans; Pyrazoles; Retrospective Studies; Thiazolidines | 2021 |
Synthesis, α-glucosidase and α-amylase inhibitory activities, acute toxicity and molecular docking studies of thiazolidine-2,4-diones derivatives.
Topics: Acarbose; alpha-Amylases; alpha-Glucosidases; Animals; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Mice; Molecular Docking Simulation; Molecular Structure; Pancreatic alpha-Amylases; Structure-Activity Relationship; Thiazolidines | 2022 |
Indian Expert Review on Use of Teneligliptin in patients with Diabetes and its Safety and Efficacy (INTENSE).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Pyrazoles; Thiazolidines | 2021 |
Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Topics: Aged; Anti-Obesity Agents; Body Mass Index; Canagliflozin; Cohort Studies; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Exercise; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Membrane Transport Modulators; Middle Aged; Overweight; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2018 |
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders.
Topics: Adult; Animals; Cell Line, Tumor; Cryopyrin-Associated Periodic Syndromes; Diabetes Mellitus, Type 2; Disease Models, Animal; HEK293 Cells; Humans; Immunoblotting; Inflammasomes; Inflammation; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microscopy, Confocal; Molecular Structure; NLR Family, Pyrin Domain-Containing 3 Protein; Small Molecule Libraries; Thiazolidines; Thiones | 2017 |
Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Chemical and Drug Induced Liver Injury; Constipation; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrazoles; Surveys and Questionnaires; Thiazolidines | 2018 |
Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Mucous Membrane; Pemphigoid, Bullous; Pyrazoles; Severity of Illness Index; Thiazolidines | 2018 |
Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
Topics: Aged; Aged, 80 and over; Autoantibodies; Autoantigens; Collagen Type XVII; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Non-Fibrillar Collagens; Pemphigoid, Bullous; Pyrazoles; Thiazolidines; Time Factors; Vildagliptin | 2018 |
Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
Topics: Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Healthy; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Pyrazoles; Thiazolidines | 2018 |
The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis.
Topics: Aged; Body Composition; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucagon-Like Peptides; Humans; Immunoglobulin Fc Fragments; Male; Middle Aged; Pyrazoles; Recombinant Fusion Proteins; Renal Dialysis; Renal Insufficiency, Chronic; Sarcopenia; Thiazolidines | 2018 |
Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
Topics: Aged; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Incidence; Japan; Male; Prognosis; Prospective Studies; Pyrazoles; Thiazolidines | 2019 |
Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Pemphigoid, Bullous; Pyrazoles; Thiazolidines; Treatment Outcome | 2018 |
An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Ligands; Molecular Docking Simulation; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Structure-Activity Relationship; Thiazolidines | 2018 |
Teneligliptin: An Economic and Effective DPP-4 Inhibitor for the Management of Type-2 Diabetes Mellitus: A Comparative Study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Pyrazoles; Thiazolidines | 2018 |
Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds.
Topics: Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Models, Biological; PPAR gamma; Quantitative Structure-Activity Relationship; Thiazolidines | 2013 |
Thiazolidin-4-one and thiazinan-4-one derivatives analogous to rosiglitazone as potential antihyperglycemic and antidyslipidemic agents.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Cell Differentiation; Cell Line; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Glucose; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Chemical; Molecular Structure; Muscle, Skeletal; Rosiglitazone; Structure-Activity Relationship; Thiazines; Thiazolidinediones; Thiazolidines; Triglycerides | 2013 |
Estimation of visceral fat and fatty liver disease using ultrasound in patients with diabetes.
Topics: Aged; Biguanides; Body Composition; Body Mass Index; Diabetes Mellitus, Type 2; Diet, Western; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intra-Abdominal Fat; Japan; Logistic Models; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Prevalence; Thiazolidines; Ultrasonography; Waist Circumference | 2014 |
Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Topics: Aged; C-Reactive Protein; Combined Modality Therapy; Deoxyglucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Prospective Studies; Pyrazoles; Serum Albumin; Thiazolidines | 2014 |
Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Topics: Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Japan; Middle Aged; Monitoring, Ambulatory; Postprandial Period; Pyrazoles; Thiazolidines | 2015 |
Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
Topics: Adult; Aged; Alanine Transaminase; Anthropometry; Biguanides; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Male; Middle Aged; Peptides; Prognosis; Retrospective Studies; Sulfonylurea Compounds; Thiazolidines; Treatment Outcome; Venoms | 2014 |
[Thiazolidine, thiazolidinediones, TZD].
Topics: Diabetes Mellitus, Type 2; Female; Humans; Male; Thiazolidinediones; Thiazolidines | 2015 |
The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Topics: Administration, Oral; Animals; Canagliflozin; Cells, Cultured; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Pyrazoles; Rats, Zucker; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2015 |
Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Psoriasis; Pyrazoles; Thiazolidines | 2015 |
Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity.
Topics: Aging; Animals; Behavior, Animal; Body Temperature Regulation; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Energy Metabolism; Female; Intra-Abdominal Fat; Liver; Macrophages; Mice, Inbred C57BL; Motor Activity; Non-alcoholic Fatty Liver Disease; Obesity, Abdominal; Ovariectomy; Panniculitis; Pyrazoles; Thiazolidines | 2015 |
Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.
Topics: Adiponectin; Aged; Deoxyglucose; Diabetes Mellitus, Type 2; Diastole; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Japan; Linear Models; Male; Middle Aged; Pyrazoles; Thiazolidines; Ventricular Function, Left | 2016 |
[The impact of glycosylated hemoglobin target value in treatment guidelines on glycemic control of type 2 diabetic in Chinese cities].
Topics: Adult; Aged; Asian People; Blood Glucose; China; Cities; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Outpatients; Sulfonylurea Compounds; Thiazolidines; Treatment Outcome | 2015 |
Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrazoles; Sitagliptin Phosphate; Thiazolidines | 2016 |
Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazoles; Renal Dialysis; Thiazolidines; Treatment Outcome | 2016 |
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nath
Topics: Algorithms; Diabetes Mellitus, Type 2; Europe; Evidence-Based Medicine; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Societies, Medical; Thiazolidines; United States | 2009 |
Thiazolidinediones and fractures in men and women.
Topics: Adult; Aged; British Columbia; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Risk; Rosiglitazone; Sex Factors; Sulfonylurea Compounds; Thiazolidinediones; Thiazolidines | 2009 |
Discovery of novel PTP1B inhibitors with antihyperglycemic activity.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Enzyme Inhibitors; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Thiazolidines | 2010 |
A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
Topics: Analysis of Variance; Animals; Body Weight; Carbohydrate Metabolism; Cell Line; Computer Simulation; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Humans; Insulin Resistance; Lipid Metabolism; Liver; Mice; Myocardial Reperfusion Injury; Oxazoles; PPAR alpha; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidines; Transfection | 2011 |
[Combination therapy of oral hypoglycemic agents which enhance the efficacy of insulin therapy].
Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sulfonylurea Compounds; Thiazolidines | 2012 |
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for t
Topics: Animals; Blood Glucose; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucose Tolerance Test; Haplorhini; Humans; Hypoglycemic Agents; Male; Molecular Docking Simulation; Pyrazoles; Rats; Rats, Wistar; Rats, Zucker; Thiazolidines | 2012 |
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin | 2012 |
An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
Topics: Age Factors; Animals; Antibodies, Monoclonal; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Fluorescent Antibody Technique, Indirect; Glomerular Mesangium; Glycation End Products, Advanced; Kidney; Kidney Glomerulus; Lysine; Rats; Rats, Inbred OLETF; Rats, Inbred Strains; Thiadiazoles; Thiazolidines | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drinking; Drug Therapy, Combination; Drug Tolerance; Eating; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Pentanoic Acids; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors | 2005 |
[(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors.
Topics: Animals; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Enzyme Inhibitors; Inhibitory Concentration 50; Models, Chemical; Molecular Conformation; Piperazine; Piperazines; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazolidines; Time Factors | 2007 |
Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidine (TZDs).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Formularies as Topic; Humans; Hypoglycemic Agents; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Male; Medical Records Systems, Computerized; Middle Aged; Pioglitazone; Quebec; Retrospective Studies; Risk Factors; Rosiglitazone; Socioeconomic Factors; Thiazolidinediones; Thiazolidines | 2008 |
Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis.
Topics: Adult; Aldehyde Reductase; Aldehydes; Atherosclerosis; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Foam Cells; Humans; Hyperlipidemias; Lipoproteins, LDL; Male; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Rhodanine; Risk Factors; Thiazolidines; Up-Regulation | 2008 |
Role of polyol pathway in nonenzymatic glycation.
Topics: Aldehyde Reductase; Animals; Cattle; Deoxyglucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Erythrocytes; Fructosephosphates; Glycation End Products, Advanced; Glycosylation; Humans; In Vitro Techniques; Polymers; Rhodanine; Serum Albumin, Bovine; Thiazolidines | 1996 |
Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Glycation End Products, Advanced; Male; Rats; Rats, Inbred Strains; Thiadiazoles; Thiazolidines | 1997 |
Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation.
Topics: Aldehyde Reductase; Autonomic Nervous System Diseases; Cardiovascular Diseases; Constipation; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Female; Gastrointestinal Motility; Hemodynamics; Humans; Intestinal Pseudo-Obstruction; Middle Aged; Rhodanine; Shock, Septic; Thiazolidines | 1997 |
Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Blood Glucose; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Erythrocytes; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Regression Analysis; Reproducibility of Results; Rhodanine; Sorbitol; Spectrophotometry; Thiazolidines | 1998 |
[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neural Conduction; Rhodanine; Thiazolidines | 1998 |
Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Aldehyde Reductase; Autonomic Nervous System Diseases; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Female; Heart; Heart Diseases; Humans; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Rhodanine; Thiazolidines; Vitamin B 12 | 1998 |
Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195.
Topics: Animals; Blood Glucose; Collagen; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelial Growth Factors; Gene Expression; Glycation End Products, Advanced; Kidney; Kidney Glomerulus; Lymphokines; Male; Rats; Rats, Inbred OLETF; RNA, Messenger; Thiadiazoles; Thiazolidines; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1999 |
Effect of aldose reductase inhibitor on cutaneous nerve fiber length in diabetic patients.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Nerve Fibers; Rhodanine; Skin; Thiazolidines | 2000 |
Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Topics: Aldehyde Reductase; Blood Glucose; Blood Proteins; Deoxyglucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Erythrocytes; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Lysine; Male; Middle Aged; Reference Values; Rhodanine; Thiazolidines | 2000 |